"

Section I: Methodologic Issues

1. Efficacy and Effectiveness: From Regulatory to Public Health Models, Barry D. Lebowitz, PhD and Herbert W. Harris, MD, PhD
2. Assessing Outcomes of Psychopharmacological Treatments in the Elderly: Evolving Considerations for Research and Clinical Practice, Joel E. Striem, MD
3. Clinical Trials Design and Analysis, Tom TenHave, PhD, MPH
4. Pharmacokinetics of Psychotropic Drugs in the Elderly, Lisa L. von Moltke, MD and David J. Greenblatt
5. Ethical Issues in Geriatric Psychopharmacologic Research, Jason H. T. Karlawish, MD and Bryan James, BS
6. Drug Use in Home Health Care: Problems and Directions for Research, Sarah Meredith, MBBS, MSc and Wayne A. Ray, PhD

Section II: Review of Selected Diseases and Syndromes

7. Treatment of Alzheimer's Disease, Lon Schneider, MD
8. Alzheimer's Disease: Behavioral Management, Rebekah Loy, PhD and Pierre N. Tariot, MD
9. Major Depression, William J. Apfeldorf, MD, PhD, and George Alexopoulos, MD
10. Substance Abuse Disorders in Late Life, David Oslin, MD and Fred Blow, PhD
11. Late Life Psychosis: Advances in Understanding and Treatment, Robert A. Sweet, MD and Bruce G. Pollock, MD, PhD
12. ECT for Geriatric Depression and Future Trends, Catherine J. Datto, MD and Sarah H. Lisanby, MD

Increasingly there will be a demand from clinicians for a better understanding of how to translate research from basic science and clinical trials into meaningful treatment recommendations for late life metal disorders. In this volume the editors have compiled the most cutting-edge research findings on common mental disorders in the elderly.

Section 1 addresses methodological issues and raises critical concerns for researchers in the field, such as how best to design and implement large clinical studies as well as how to translate their finding into practice for mental health providers.

Section II focuses on treatment for specific diseases such as late life depression, substance abuse, and psychosis. Of particular note are chapters behavioral treatments for persons with Alzheimerís Disease.

For clinicians and researchers in the field of gerontology and geriatrics.